Biosignal-guided personalized therapy

Sudden cardiac death (SCD) is the leading single cause of death in the industrialized world. Current guidelines recommend a prophylactic implantation of an implantable cardioverter-defibrillator (ICD) in patients with reduced left-ventricular ejection fraction (LVEF ≤ 35%). However, most deaths afte...

Full description

Bibliographic Details
Main Authors: von Stülpnagel Lukas, Wolf Bernhard, Bauer Axel
Format: Article
Language:English
Published: De Gruyter 2017-09-01
Series:Current Directions in Biomedical Engineering
Subjects:
Online Access:https://doi.org/10.1515/cdbme-2017-0037
id doaj-309f0c005b3d48e8bcd368bf72c16445
record_format Article
spelling doaj-309f0c005b3d48e8bcd368bf72c164452021-09-06T19:19:24ZengDe GruyterCurrent Directions in Biomedical Engineering2364-55042017-09-013217918110.1515/cdbme-2017-0037cdbme-2017-0037Biosignal-guided personalized therapyvon Stülpnagel Lukas0Wolf Bernhard1Bauer Axel2Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Marchioninistr. 15, 81377 München, GermanyFakultät für Elektro- und Informationstechnik, Technische Universität München, Theresienstr. 90, 80339 München, GermanyMedizinische Klinik und Poliklinik I, Klinikum der Universität München, Marchioninistr. 15, 81377 München, GermanySudden cardiac death (SCD) is the leading single cause of death in the industrialized world. Current guidelines recommend a prophylactic implantation of an implantable cardioverter-defibrillator (ICD) in patients with reduced left-ventricular ejection fraction (LVEF ≤ 35%). However, most deaths after myocardial infarction (MI) occur in patients with normal or moderately reduced LVEF (>35%). There is a large body of evidence that cardiac autonomic dysfunction after MI is linked to increased susceptibility to malignant arrhythmias. Deceleration capacity of heart rate (DC) and periodic repolarization dynamics (PRD) are novel ECG-based risk markers, which capture different facets of cardiac autonomic dysfunction. Both parameters are strong and independent predictors of mortality and SCD after MI. Previous studies indicated that combined assessment of DC and PRD allows identification of a new high-risk group among post-infarction patients that is not addressed by current guidelines, thus opening new perspectives for biosignal-guided personalized therapies.https://doi.org/10.1515/cdbme-2017-0037sudden deathrisk stratificationautonomic nervous system
collection DOAJ
language English
format Article
sources DOAJ
author von Stülpnagel Lukas
Wolf Bernhard
Bauer Axel
spellingShingle von Stülpnagel Lukas
Wolf Bernhard
Bauer Axel
Biosignal-guided personalized therapy
Current Directions in Biomedical Engineering
sudden death
risk stratification
autonomic nervous system
author_facet von Stülpnagel Lukas
Wolf Bernhard
Bauer Axel
author_sort von Stülpnagel Lukas
title Biosignal-guided personalized therapy
title_short Biosignal-guided personalized therapy
title_full Biosignal-guided personalized therapy
title_fullStr Biosignal-guided personalized therapy
title_full_unstemmed Biosignal-guided personalized therapy
title_sort biosignal-guided personalized therapy
publisher De Gruyter
series Current Directions in Biomedical Engineering
issn 2364-5504
publishDate 2017-09-01
description Sudden cardiac death (SCD) is the leading single cause of death in the industrialized world. Current guidelines recommend a prophylactic implantation of an implantable cardioverter-defibrillator (ICD) in patients with reduced left-ventricular ejection fraction (LVEF ≤ 35%). However, most deaths after myocardial infarction (MI) occur in patients with normal or moderately reduced LVEF (>35%). There is a large body of evidence that cardiac autonomic dysfunction after MI is linked to increased susceptibility to malignant arrhythmias. Deceleration capacity of heart rate (DC) and periodic repolarization dynamics (PRD) are novel ECG-based risk markers, which capture different facets of cardiac autonomic dysfunction. Both parameters are strong and independent predictors of mortality and SCD after MI. Previous studies indicated that combined assessment of DC and PRD allows identification of a new high-risk group among post-infarction patients that is not addressed by current guidelines, thus opening new perspectives for biosignal-guided personalized therapies.
topic sudden death
risk stratification
autonomic nervous system
url https://doi.org/10.1515/cdbme-2017-0037
work_keys_str_mv AT vonstulpnagellukas biosignalguidedpersonalizedtherapy
AT wolfbernhard biosignalguidedpersonalizedtherapy
AT baueraxel biosignalguidedpersonalizedtherapy
_version_ 1717778687306235904